Sutro Biopharma, Inc. (STRO): Price and Financial Metrics
GET POWR RATINGS... FREE!
STRO POWR Grades
- Value is the dimension where STRO ranks best; there it ranks ahead of 71.76% of US stocks.
- STRO's strongest trending metric is Momentum; it's been moving down over the last 29.7142857142857 weeks.
- STRO ranks lowest in Momentum; there it ranks in the 11th percentile.
STRO Stock Summary
- STRO's went public 2.64 years ago, making it older than only 6.73% of listed US stocks we're tracking.
- STRO's price/sales ratio is 18.17; that's higher than the P/S ratio of 89.7% of US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for STRO comes in at -28.06% -- higher than that of merely 10.22% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Sutro Biopharma Inc are RNA, LTRX, DAIO, CSLT, and GTYH.
- Visit STRO's SEC page to see the company's official filings. To visit the company's web site, go to www.sutrobio.com.
STRO Stock Price Chart Interactive Chart >
STRO Price/Volume Stats
|Current price||$20.23||52-week high||$28.30|
|Prev. close||$19.79||52-week low||$7.06|
|Day high||$20.37||Avg. volume||504,683|
|50-day MA||$21.25||Dividend yield||N/A|
|200-day MA||$17.99||Market Cap||932.87M|
Sutro Biopharma, Inc. (STRO) Company Bio
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company’s product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was founded in 2003 and is based in South San Francisco, California.
STRO Latest News Stream
|Loading, please wait...|
STRO Latest Social Stream
View Full STRO Social Stream
Latest STRO News From Around the Web
Below are the latest news stories about Sutro Biopharma Inc that investors may wish to consider to help them evaluate STRO as an investment opportunity.
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Chief Executive Officer, Bill Newell, will present at two upcoming virtual investor conferences on May 20 and June 2, 2021.
News Flash: Analysts Just Made A Substantial Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Forecasts
Sutro Biopharma, Inc. ( NASDAQ:STRO ) shareholders will have a reason to smile today, with the analysts making...
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 29.51% and 111.97%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma Reports First Quarter 2021 Financial Results, Business Highlights and 2021 Anticipated Milestones
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today reported its financial results for the quarter ended March 31, 2021, its recent business highlights, and provided a preview of anticipated selected milestones in 2021.
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Merck, known as MSD outside the United States and Canada, will make to Sutro a $15 million milestone payment for the initiation of an IND enabling toxicology study for the first program in its collaboration to develop novel cytokine derivative therapeutics for cancer and autoimmune disorders. In July 2018, Sutro entered into a collaboration with Merck to jointly discover and develop best-in-class immune-modulating cytokine derivatives for both oncology and autoimmune indications.
STRO Price Returns